Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Bumped as per requests from yesterday
————————————————————————————-
It’s going to be the only way to attend practically anything and anywhere with a crowd
Concerts,Pubs,Restaurants, Sports events, Airports,Hotels,Work,University ,Theme parks, Night clubs and so on , with our without been Vaccinated !
And World wide in a lot of cases
Short term and long term future going to bright for ODX if managed properly commercially
GLA LTHKkk
It’s going to be the only way to attend practically anything and anywhere with a crowd
Concerts,Pubs,Restaurants, Sports events, Airports,Hotels,Work,University ,Theme parks, Night clubs and so on , with our without been Vaccinated !
And World wide in a lot of cases
Short term and long term future going to bright for ODX if managed properly commercially
GLA LTH
BREAKING: Boris Johnson to hold press conference on coronavirus - 3pm
Probably about Booster Jabs etc ,but you never know !
GLA LTH
Sorry you think that calderkate,
its just my opinion on a in the main opinion related forum
Maybe a change from the norm of late
GLA LTH
Unfortunately Colin and all of us LTH have been time warped and hood winked by the Government over false dawns.
ODX have been too inexperienced to believe and hope that a Government contract was coming and coming and coming !!!
Eggs all in one basket i am afraid
Lessons need to be learnt for the future
i certainly believe it will happen ,but in any business you need a plan b
GLA LTH
Illegal !!! ffs
CTDA regs was from 1/11...........Monday !!!!!!
Colin announces Dam Health 2/11 .......Tuesday !!!!!!!
Colin announces Ctda regs 3/11..............Weds !!!!!!!!
its called common business sense
GLA LTH
Yesterday 7.00am
Rns number 1 ; Todays Rns about the list
10 seconds later
Rns number 2; Partnership with Dam Health
Job done
one fights against the other
Basic way imo
GLA LTH
Hopefully we don’t suffer a double whammy by dropping again today after yesterday’s on the back’ of other companies notifications of the situation
GLA LTH
Neither Avacta or Nyct
Update on UK Availability of AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test following Implementation of CTDA Regulations
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, notes that, as of 1 November 2021, the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA regulations") have come into force. Consistent with these new regulations the Company has suspended, as of 1 November 2021, further sales of its AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test in the UK until the ongoing desktop evaluation of the test has been successfully completed by the Agency and the test subsequently is put on the CTDA register for approved products. This is a new requirement for the supply of any COVID-19 test in the UK and is over and above the CE mark and successful registration of Company's AffiDX test with the MHRA which was announced on 7 June 2021.
The new CTDA Regulations stipulate that all suppliers of COVID-19 tests must submit information regarding their products for desktop review if they wish to remain on sale in the UK. As of 1 November 2021, there were only three products for which the Agency had completed its desktop review listed on the CTDA register for approved products. Additionally, the UK Health Security Agency has published a temporary protocol which lists 48 tests (both PCR and antigen based) which passed the Public Health England validation process at Porton Down earlier in the year that can remain available for sale in the UK whilst their validation is completed until a cut-off date of 28 February 2022.
Avacta submitted, ahead of the 1 September 2021 deadline, all the information required for its AffiDX test to be validated under these regulations by the UK Health Security Agency, and the Company has paid the required fee. The Company awaits further notification from the UK Health Security Agency when it completes its review of the information supplied for the AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test.
The impact of suspension of sales in the UK as a result of the CTDA regulations coming into force will not have a material impact on the Company's anticipated financial outturn for the financial year ending 31 December 2021. As previously noted, Avacta continues to focus on opportunities outside of the UK for the sale and marketing of its AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test including markets in Europe and further afield.
Well done Omega , first scratch of the order pad, plenty more to come ..
GLA LTH
It’s not going anywhere , it will be controlled more and more , look at Flu ,it can be controlled but not wiped out
Jabs and testing is here for a lot longer than all us on here will be around
Let’s hope ODX get it right and are part of that future
GLA LTH
Just topped up 116,851 , typical showing as a sell !!!
First time for a long time averaged up on a share ....................roll on 4.10 and then the wife will not be moaning at me when i told her to buy many months ago at that price in fear of missing out !
GLA LTH
Test-To-Go System powered by MagnifEye receives European regulatory certification
Oxford, U.K. and Dover, Delaware, USA, 21 October 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company") the ethical Clinical AI company, today announces that its licence and development partner, Excalibur Healthcare Services Limited ("Excalibur"), has received European regulatory certification, which includes the UK, for its 'Test-To-Go' COVID-19 antigen testing system powered by Sensyne's MagnifEyeÔ.
The Test-To-Go system powered by MagnifEye includes the Excalibur lateral flow test ("LFT") CE-marked for self-testing, as well as the CE marked 'Test to Go app', which includes Sensyne's AI-powered image analysis technology MagnifEyeÔ which provides AI-enabled automated accurate and consistent reading of Excalibur LFT results.
Excalibur together with Sensyne will work to drive adoption and use throughout the European Economic Area and the United Kingdom in the use of COVID-19 lateral flow testing across commercial and government settings.
MagnifEye is already being used as part of the Department of Health & Social Care's COVID-19 testing programme in the NHS and has read and recorded more than one million lateral flow antigen tests to date. Independent research has shown that the use of MagnifEye significantly increases the reading accuracy of lateral flow testing.[1]
yeah pal 25p launch price (which i bought into ) and 49.5 high
sorry calculator was wrong , it should have been 98%
50p
100% up on Launch Price , in 5 weeks as well !
Sing along Colin .
Fingers crossed
GLA LTH